Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levonorgestrel-releasing intrauterine system vs etonogestrel subdermal implant
- Development stage
- Approved
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Intrauterine, Subcutaneous
01
Overview
g_CLEANED-University of Campinas, Brazil-endometriosis refers to a Phase 4 clinical trial (NCT02233413) comparing the efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS, brand name Mirena) and the etonogestrel-releasing subdermal implant (ENG, brand name Implanon) for the management of endometriosis-associated pelvic pain. Both systems are long-acting reversible contraceptives (LARCs) that function as hormonal therapies. The LNG-IUS is a T-shaped device inserted into the uterus that releases levonorgestrel locally, while the etonogestrel implant is a single-rod device placed subcutaneously in the arm. Both drugs act as progesterone receptor agonists, leading to endometrial suppression and atrophy, which alleviates symptoms such as dysmenorrhea and chronic pelvic pain in women with endometriosis.
- Brand names
- MirenaImplanon
- Other names
- LNG-IUSENG implantetonogestrel subdermal implantlevonorgestrel-releasing intrauterine system
02
Targets
PR (Progesterone receptor)GR (Glucocorticoid receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on levonorgestrel-releasing intrauterine system vs etonogestrel subdermal implant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levonorgestrel-releasing intrauterine system vs etonogestrel subdermal implant.